Epstein-barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan
Journal
Cancer Epidemiology Biomarkers and Prevention
Journal Volume
23
Journal Issue
7
Pages
1213-1219
Date Issued
2014
Author(s)
Coghill A.E
Hsu W.-L
Pfeiffer R.M
Juwana H
Yu K.J
Chen J.-Y
Chen C.-J
Middeldorp J.M
Hildesheim A.
Abstract
Background: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated cancer that is highly treatable when diagnosed early, with 5-year disease-free survival of approximately 90%. However,NPC is typically diagnosed at advanced stages, in which disease-free survival is <50%. There is, therefore, a need for clinical tools to assist in early NPC detection, particularly among high-risk individuals. Methods: We evaluated the ability of anti-EBV IgA antibodies to detect incident NPC among high-risk Taiwanese individuals. NPC cases (N = 21) and age- and sex-matched controls (N = 84) were selected. Serum collected beforeNPCdiagnosis was tested for ELISA-based IgA antibodies against the following EBV peptides: EBNA1, VCAp18, EAp138, Ead-p47, and VCAp18 + EBNA1 peptide mixture. The sensitivity, specificity, and screening program parameters were calculated. Results: EBNA1 IgA had the best performance characteristics. At an optimized threshold value, EBNA1 IgA measured at baseline identified 80% of the high-risk individuals who developed NPC during follow-up (80% sensitivity). However, approximately 40% of high-risk individuals who did not develop NPC also tested positive (false positives). Application of EBNA1 IgA as a biomarker to detect incident NPC in a previously unscreened, high-risk population revealed that 164 individuals needed to be screened to detect 1 NPC and that 69 individuals tested positive per case detected. Conclusions:EBNA1IgA proved to be a sensitive biomarker for identifying incident NPC, but future work is warranted to develop more specific screening tools to decrease the number of false positives. Impact: Results fromthis study could informdecisions about screening biomarkers and referral thresholds for future NPC early-detection program evaluations. ? 2014 American Association for Cancer Research.
SDGs
Other Subjects
biological marker; early antigen p138; early antigen p47; Epstein Barr virus antigen; Epstein Barr virus antigen 1; immunoglobulin A antibody; unclassified drug; virus capsid antigen 18; EBV-encoded nuclear antigen 1; Epstein Barr virus antigen; immunoglobulin A; virus antibody; adult; antibody blood level; antibody titer; article; cancer diagnosis; cancer screening; controlled study; diagnostic test accuracy study; enzyme linked immunosorbent assay; Epstein Barr virus; false positive result; family; female; follow up; high risk patient; high risk population; human; major clinical study; male; nasopharynx carcinoma; priority journal; sensitivity and specificity; serology; Taiwan; aged; area under the curve; blood; complication; early diagnosis; Epstein Barr virus infection; laboratory diagnosis; middle aged; nasopharynx tumor; procedures; receiver operating characteristic; virology; Adult; Aged; Antibodies, Viral; Area Under Curve; Early Detection of Cancer; Enzyme-Linked Immunosorbent Assay; Epstein-Barr Virus Infections; Epstein-Barr Virus Nuclear Antigens; False Positive Reactions; Humans; Immunoglobulin A; Male; Middle Aged; Nasopharyngeal Neoplasms; ROC Curve; Sensitivity and Specificity; Taiwan
Publisher
American Association for Cancer Research Inc.
Type
journal article